Aptose Biosciences Inc. (APTO) Receives Buy Rating from Roth Capital
A number of other analysts also recently commented on APTO. Canaccord Genuity restated a buy rating and set a $7.00 price target on shares of Aptose Biosciences in a research report on Saturday. Zacks Investment Research upgraded shares of Aptose Biosciences from a sell rating to a hold rating in a report on Tuesday, October 11th. Royal Bank Of Canada reiterated an outperform rating and issued a $23.00 target price on shares of Aptose Biosciences in a report on Saturday, June 25th. Finally, RBC Capital Markets reissued an outperform rating on shares of Aptose Biosciences in a research report on Tuesday, September 13th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. Aptose Biosciences currently has an average rating of Buy and a consensus price target of $12.30.
Shares of Aptose Biosciences (NASDAQ:APTO) traded down 9.17% on Friday, reaching $2.18. 35,115 shares of the company’s stock traded hands. Aptose Biosciences has a 52 week low of $1.92 and a 52 week high of $6.40. The company has a 50 day moving average price of $2.22 and a 200 day moving average price of $2.47. The firm’s market capitalization is $28.10 million.
A hedge fund recently bought a new stake in Aptose Biosciences stock. Bank of Montreal Can bought a new position in shares of Aptose Biosciences Inc. (NASDAQ:APTO) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 52,624 shares of the company’s stock, valued at approximately $128,000. Bank of Montreal Can owned about 0.43% of Aptose Biosciences as of its most recent filing with the SEC. 19.47% of the stock is owned by institutional investors.
About Aptose Biosciences
Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.
Receive News & Stock Ratings for Aptose Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences Inc. and related stocks with our FREE daily email newsletter.